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http://dx.doi.org/10.1016/j.ccell.2015.09.001SUMMARYhnRNP K regulates cellular programs, and changes in its expression and mutational status have been impli-
cated in neoplastic malignancies. To directly examine its role in tumorigenesis, we generated amousemodel
harboring an Hnrnpk knockout allele (Hnrnpk+/). Hnrnpk haploinsufficiency resulted in reduced survival,
increased tumor formation, genomic instability, and the development of transplantable hematopoietic neo-
plasms with myeloproliferation. Reduced hnRNP K expression attenuated p21 activation, downregulated
C/EBP levels, and activated STAT3 signaling. Additionally, analysis of samples from primary acute myeloid
leukemia patients harboring a partial deletion of chromosome 9 revealed a significant decrease in HNRNPK
expression. Together, these data implicate hnRNP K in the development of hematological disorders and
suggest hnRNP K acts as a tumor suppressor.INTRODUCTION
Cytogenetic alterations and chromosomal deletions are often
observed in cancers. Recurrent genetic losses are thought to
contribute to disease processes through deregulating critical
cellular programs that govern proliferation and differentiation
(Burnett et al., 2011; Mro´zek et al., 2007). However, even though
these genetic alterations can be clinically identified, we often do
not fully understand which gene(s) are responsible for driving a
particular malignancy. For example, it is well established that
9q deletions are recurrent abnormalities in myeloid neoplasias
and are present in 2% of acute myeloid leukemias (AMLs);
however, which gene(s) are responsible for the pathogenesis ofSignificance
Deletion of the 9q21.32 locus is observed in some patients with
HNRNPK is an attractive candidate, as it is one of six genes ma
whenmutated. Here, we show that AML patients harboring this
strate through an animalmodel thatHnrnpk haploinsufficiency
aberrant p21 and C/EBP expression, and Stat3 activation. Thes
ficient tumor suppressor and may underpin the pathogenesis
tigating potential hnRNP-K-mediated tumor suppressor pathw
486 Cancer Cell 28, 486–499, October 12, 2015 ª2015 Elsevier Inc.this disease remains unclear (Mecucci et al., 1984). In a subset
of AMLs harboring 9q deletions, the 9q21.32 locus is specifically
lost, suggesting a tumor suppressor resides at this locus and its
haploinsufficiency contributes to disease progression (Dayyani
et al., 2008; Kro¨nke et al., 2013; Sweetser et al., 2005). A recent
study mapped six possible candidate genes to the minimally
deleted region (MDR) of chromosome 9q21.32 (Kro¨nke et al.,
2013). Of these six genes, the DNA and RNA binding protein,
Heterogeneous Nuclear Ribonuclear Protein K (HNRNPK), is an
intriguing potential tumor suppressor.
Mutational analyses of AML patient samples by The Cancer
Genome Atlas revealed that hnRNP K mutations may drive
AML progression, implicating the potential involvement ofAML, suggesting a tumor suppressor resides in this region.
pped to this region and is thought to drive AML progression
deletion have reducedHNRNPK expression, andwe demon-
results in significant hematologic andmalignant phenotypes,
e data provide evidence that hnRNP K acts as a haploinsuf-
of a subset of AML, which may open new frontiers in inves-
ays.
Figure 1. HNRNPK Expression Is Reduced in Patients with AML that
Harbor a 9q Deletion
qRT-PCR analysis of HNRNPK levels from bone marrow aspirates of AML
patients who carry 9q deletions (n = 12) and healthy donors controls (n = 8)
(p = 0.0001). Data are represented as mean ± SEM determined from triplicate
samples after normalization to the geometric mean of b-ACTIN and GAPDH.
***p < 0.005. p values were calculated using the Mann-Whitney test.hnRNP K in leukemogenesis (Cancer Genome Atlas Research
Network, 2013). Furthermore, in vitro studies suggest that
altered hnRNP K expression may contribute to cancer pheno-
types through its transcriptional and translational regulation of
genes that control proliferation and differentiation programs
(Liu and Szaro, 2011; Notari et al., 2006; van Domselaar et al.,
2012; Wang et al., 2011).
It is currently unclear how aberrant hnRNP K expression
contributes to tumor phenotypes in vivo, as underexpression,
overexpression, andmutations have all been have been reported
in patient samples. On one hand, several studies suggest
increased hnRNP K expression results in a potential oncogenic
effect through regulation of c-Myc (Notari et al., 2006; Roy-
choudhury and Chaudhuri, 2007). However, much of our under-
standing of hnRNP K’s potential role in tumorigenesis stems
frombiochemical and cell line studies demonstrating that hnRNP
K acts as a transcriptional co-activator of p53-dependent p21
expression, suggesting a potential role in tumor suppression
(Enge et al., 2009; Moumen et al., 2005). Furthermore, in vitro
studies have shown that hnRNP K controls programs that
influence differentiation potential in hematopoietic stem cells
(HSCs), which may ultimately impact leukemogenesis (Ostar-
eck-Lederer and Ostareck, 2012). Additionally, other studies
have shown that hnRNP K represses C/EBPb-mediated differen-
tiation in the liver and that it regulates the expression of genes
required for hematopoietic maturation (Miau et al., 1998; Ostar-
eck et al., 1997). Together, these studies suggest hnRNP K
plays a critical role in proliferation and differentiation and that
deregulation of hnRNP K expression may promote tumorigen-
esis (Liu and Szaro, 2011; Mikula et al., 2013; van Domselaar
et al., 2012; Wang et al., 2011).CTo understand how hnRNP K functionally influences hemato-
poiesis and tumorigenesis in vivo, we generated an Hnrnpk hap-
loinsufficient mouse model (Hnrnpk+/) that potentially mimics
the putative haploinsufficiency observed in AML patients with
9q21.32 deletions.
RESULTS
HNRNPK Expression Is Reduced in Patients with AML
that Harbor 9q Deletions
Alterations in the long arm of chromosome 9 (9q) are recurrent
genetic anomalies observed in AML. In a subset of individual
patients with AML, the 9q21.32 genomic section containing the
HNRNPK gene is specifically lost, suggesting a tumor suppres-
sor may reside at this locus (Kro¨nke et al., 2013). To evaluate a
potential link between HNRNPK expression and AML, we exam-
ined HNRNPK expression levels in patients with 9q21.32 dele-
tions. Analysis of CD34+ primary bone marrow samples from
these patients (n = 12) revealed HNRNPK expression is signifi-
cantly reduced when compared with CD34+ bone marrow cells
from healthy donors (n = 8) (Figure 1, p = 0.0001), suggesting
reduced HNRNPK expression may contribute to the etiology of
myeloid malignancies.
Generation of Hnrnpk Haploinsufficient Mice
Biochemical and cell-based studies have previously been
employed to examine the role of hnRNP K in regulating cellular
processes (Gao et al., 2009; Notari et al., 2006; van Domselaar
et al., 2012; Wang et al., 2011). However, in vivo evaluation of
hnRNP K has been limited because of the lack of animal models.
Thus, to directly examine the biological functions of hnRNP K,
we used mouse embryonic stem cells (mESCs) generated by
the Knockout Mouse Project (KOMP) consortium that harbor
an Hnrnpk knockout allele (Hnrnpktm1(KOMP)Wtsi) to generate
Hnrnpk+/ chimeric mice (Figure 2A). However, after screening
more than 400 potential offspring on the C57Bl/6 background,
only one Hnrnpk+/ mouse was generated (data not shown).
This single mouse (male) rapidly developed a lymphoma and
became moribund; however, prior to death, sperm was isolated
and used for in vitro fertilization to generate Hnrnpk+/ mice on
the Balb/C background. Germline transmission, validation of
targeted recombination, evaluation of recombination sites, and
verification of the absence of mutations were confirmed by
PCR analyses using internal and external primers followed by
DNA sequencing (Figure 2B; Figures S1A and S1B). Cre-medi-
ated deletion of the neomycin cassette and Flp-mediated dele-
tion of the LacZ and neomycin cassettes were confirmed by
PCR analyses (Figure S1C).
Biallelic Loss of Hnrnpk Results in Embryonic Lethality,
while Haploinsufficiency Results in Developmental
Defects
Hnrnpk+/ mice were born at reduced Mendelian ratio, and a
significant portion of Hnrnpk+/ mice that were born died prior
to weaning (31 of 103, 30%), typically within the first several
days of life (Figure 3A). Hnrnpk+/ mice that did survive past
weaning (21 days) displayed a pronounced retardation in growth
compared with wild-type littermates (Figures 3B and 3C). This
reduced growth persisted throughout the life of these mice, asancer Cell 28, 486–499, October 12, 2015 ª2015 Elsevier Inc. 487
AB
Figure 2. Generation of Hnrnpk Haploinsufficient Mice
(A) Schema of the Hnrnpk locus and the KOMP targeting vector (Hnrnpktm1(KOMP)Wtsi). The targeting vector replaced exons 3 through 6 and with a neomycin
selectable marker flanked by LoxP sites (ovals) and LacZ cassette flanked by Flp sites (arrowheads). Black numbered boxes denote Hnrnpk exons.
(B) PCR analysis of targeted recombination in Hnrnpk+/ mice. The 5.9-kb amplicon (dark blue arrowheads) represents the recombined Hnrnpk allele using
external and internal primers for the 50 arm. Wild-type (WT) DNA serves as a negative control. The 10.1-kb (black arrowheads), 9.1-kb (red arrowheads), 8.1-kb
(green arrowheads), and 5.5-kb (light blue arrowheads) amplicons represent the recombined Hnrnpk allele using external and internal primers for the 30 arm. M,
1-kb marker.
See also Figure S1.both male and female Hnrnpk+/ mice were significantly smaller
than their wild-type counterparts at 6 months (female, 25.74 ±
0.97 g versus 20.57 ± 0.81 g [p = 0.011]; male, 32.38 ± 2.49 g
versus 19.72 ± 1.89 g [p = 0.004]), respectively (Figure 3D).
We next sought to generate a cohort of Hnrnpk null mice
(Hnrnpk/); however, we were unable to obtain mice harboring
biallelic deletion of Hnrnpk (Figure 3E). These results suggest
loss of Hnrnpk is incompatible with embryonic survival, while
reduced hnRNP K expression causes pleiotropic effects that
impact neonatal survival and development.
Given the Hnrnpk-null lethality, our attention was focused on
investigating the potential impact of Hnrnpk haploinsufficiency.
We evaluated expression changes resulting from deletion of
one Hnrnpk allele by examining hnRNP K levels in tissues from
Hnrnpk+/ and wild-type mice. Western blot and qRT-PCR
analysis of Hnrnpk+/ spleens, bone marrow, livers, and mouse
embryo fibroblasts (MEFs) revealed a significant decrease in
hnRNP K levels compared with their wild-type littermates (Fig-488 Cancer Cell 28, 486–499, October 12, 2015 ª2015 Elsevier Inc.ures 3F and 3G). Together, these results demonstrate that loss
of one Hnrnpk allele significantly diminished hnRNP K levels
and identified reduced hnRNP K expression as a causal factor
in the Hnrnpk haploinsufficient phenotypes.
The p53/p21 Pathway Is Altered in Hnrnpk+/– Mice
Previous biochemical and pharmacological analyses have impli-
cated hnRNP K in directly regulating p21 expression through
the p53 pathway (Enge et al., 2009;Moumen et al., 2005). To pre-
cisely evaluate a link between hnRNP K and p21 expression in a
genetically defined model, we attempted to generate Hnrnpk/
MEFs to examine potential hnRNP-K-mediated proliferation
changes. We were unable to obtain Hnrnpk null MEFs as
Hnrnpk/ embryos either failed to form or died in utero prior
to day 13.5 (data not shown). We were, however, successful in
generating Hnrnpk+/ MEFs and used these MEFs to evaluate
the impact that reduced hnRNPK expression has on proliferation
potential. Hnrnpk+/ MEFs had a growth advantage compared
AC
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B Figure 3. Hnrnpk
+/– Mice Have Develop-
mental Defects and Reduced hnRNP K
Expression
(A) Observed and expected number of Hnrnpk+/
and wild-type mice at weaning (21 days).
(B) Growth retardation in Hnrnpk+/ mice at day 3
(left) and 10 days (right).
(C) Weight (in grams) of Hnrnpk+/ (n = 10) and
wild-type littermates (n = 8) over the first 4 weeks
of life (p = 0.0001).
(D) Weight analysis (in grams) of adult Hnrnpk+/
and wild-type mice stratified by sex (female, p =
0.011; male, p = 0.003).
(E) Observed and expected ratio of Hnrnpk/,
Hnrnpk+/, and wild-type mice from 12 separate
Hnrnpk+/ matings at weaning (21 days).
(F) qRT-PCR analysis of Hnrnpk expression in the
bone marrow of wild-type (n = 4) and Hnrnpk+/
(n = 4) mice (p = 0.0396).
(G) Western blot analyses of hnRNP K levels in
lysates from wild-type and Hnrnpk+/ mice (upper
left panel: MEFs; upper right panel: whole bone
marrow; bottom left panel: spleen; bottom right
panel: liver).
Data are represented as mean ± SEM. *p < 0.05
and ***p < 0.005. p values were calculated using
the Mann-Whitney test.with wild-type MEFs (Figures 4A and S2). Given the proposed
role of hnRNP K as a regulator of p53-dependent p21 expres-
sion, we next evaluated p21 levels in wild-type and Hnrnpk+/
MEFs following g-irradiation and observed Hnrnpk+/ MEFs
did not fully transcriptionally activate p21 expression (Figure 4B),
resulting in reduced p21 levels (Figure 4C). These data suggest
that hnRNP K directly contributes to regulating the antiprolifera-
tive effects of p53 activities at the p21 promoter.
Decreased hnRNP K Expression Results in Myeloid
Hyperplasia
Hematopoietic cells undergo constant cycles of self-renewal
and differentiation, making them extremely sensitive to genetic
alterations that disrupt proliferation and differentiation programs
(Seita and Weissman, 2010). Given that hnRNP K has been
implicated in regulating differentiation potential, we next evalu-
ated whether reduced hnRNP K expression impacts hemato-
poietic processes by evaluating complete blood counts fromCancer Cell 28, 486–499,the peripheral blood of Hnrnpk+/ mice.
Hnrnpk+/mice had a significant increase
in the number and percentage of neutro-
phils (29.37 3 103/ml ± 3.96 3 103/ml
versus 12.10 3 103/ml ± 2.24 3 103/ml;
p = 0.0035), basophils (0.19 3 103/ml ±
0.046 3 103/ml versus 0.083 3 103/ml ±
0.019 3 103/ml; p = 0.0477), and platelets
(1,858 3 103/ml ± 126.8 3 103/ml versus
992.3 3 103/ml ± 87.05 3 103/ml; p =
0.0095) compared with wild-type mice
(Figure 5A; Figure S3). Additionally, flow
cytometry revealed that reduced hnRNP
K expression resulted in a significant in-crease in CD11b/LyG6 double positive cells (markers of mature
granulocytes) in the peripheral blood of Hnrnpk+/ mice
compared with wild-type mice (25.42% ± 15.72% versus
12.93% ± 11.06%, respectively, p = 0.0354) and bone marrow
(53.76% ± 8.61% versus 30.17% ± 13.98%; respectively, p =
0.008) (Figure 5B). These findings indicate that Hnrnpk haploin-
sufficiency promotes a myeloproliferative phenotype.
Hnrnpk+/– Mice Have Reduced Survival and Are Tumor
Prone
To evaluate the long-term consequence of reduced hnRNP K
expression, a cohort of Hnrnpk+/ mice were generated and
monitored for changes in survival. To minimize the impact that
the Hnrnpk-dependent neonatal lethal phenotype would have
on our survival analyses, only Hnrnpk+/ mice that survived
past 21 days (weaning) were included in our survival com-
parisons.Hnrnpk+/mice showed a significant decrease in over-
all survival compared with wild-type littermates (p = 0.0001)October 12, 2015 ª2015 Elsevier Inc. 489
A B C Figure 4. Reduced hnRNP K Expression Re-
sults in Increased Proliferation and a Damp-
ened p21 Response following DNA Damage
(A) Increased cell proliferation in Hnrnpk+/ MEFs.
Three low passage (P2) MEF cell lines per genotype
were plated for 24, 48, or 72 hr and then assayed by
WST-8 (p = 0.0070). Each data point represents
the mean ± SEM for three separate MEF lines per
genotype.
(B) qRT-PCR analysis of p21 levels before and after
irradiation from WT and Hnrnpk+/ MEFs.
(C) Western blot analysis of hnRNP K and p21
expression in lysates from g-irradiation treated
wild-type and Hnrnpk+/ MEFs. b-actin serves as
an internal control.
Data are represented as mean ± SEM. ***p < 0.005.
p values were calculated using unpaired t and
Mann-Whitney tests. See also Figure S2.(Figure 6A). The median overall survival for the Hnrnpk+/ mice
was 474 days, while wild-type mice have not reached the 50%
survival by that time point (hazard ratio = 5.45; confidence inter-
val = 3.30 to 9.12).
To explore the causes of this reduced survival, moribund
Hnrnpk+/ mice were sacrificed and tissues were harvested
for evaluation. Pathological analyses revealed that Hnrnpk+/
mice had a proclivity to develop hematologic malignances,
as the majority of Hnrnpk+/ mice pathologically analyzed
(34 out of 55; 62%) displayed a significant myeloproliferative
phenotype (Figures 6B and 6C). To investigate the basis of
these myeloproliferative phenotypes, we performed karyotype
analyses and observed that hnRNP K expression resulted in
significant genomic instability as cells from Hnrnpk+/ bone
marrows had frequent structural aberrations compared with
wild-type control bone marrows (Figure S4A). Hnrnpk+/ bone
marrows exhibited at least one genomic alteration, with the
majority being fusions (93%) and the remaining 7% breaks.
Additionally, 29% of the total bone marrow cells analyzed
contained polyploidy cells. These observations suggest that
Hnrnpk loss contributes to tumorigenesis through its regu-
lation of genomic stability. Even though we routinely observed
Hnrnpk+/ bone marrows packed with myeloid cells that
harbored chromosomal abnormalities, this did not often result
in a significant impact in splenic size. This lack of difference
in splenic volume was attributed to the significant overall
reduction in the size of the Hnrnpk+/ compared with wild-
type littermates (Figure 3C). Accordingly, analyses of organ
weights revealed that Hnrnpk+/ mice had significantly smaller
spleens (0.045 ± 0.024 g, n = 7) than age-matched wild-type
control mice (0.14 ± 0.07 g, n = 3; p = 0.0357).
In addition to myeloproliferative phenotypes, Hnrnpk+/ mice
also frequently harbored other hematologic malignancies. Lym-
phomas were observed in 31% (17 out of 55) of Hnrnpk+/ mice
(Figures 6B, 6D, and 6E). To determine the cell of origin of these
Hnrnpk+/-dependent lymphomas, we evaluated the expression
of lineage-specific lymphoid markers. Lymphomas from these
Hnrnpk+/mice expressed either T cell (CD3) or B cell (B220) sur-
face markers, indicating that reduced hnRNP K expression pro-
motes both T and B cell lymphomas (Figure 6E, right panels).
Furthermore, we observed a thrombocytosis-like phenotype
in some Hnrnpk+/ mice, as reduced hnRNP K expression often490 Cancer Cell 28, 486–499, October 12, 2015 ª2015 Elsevier Inc.resulted in increased megakaryopoesies (Figure S4B). In addi-
tion to the pronounced hematopoietic phenotypes, we observed
that two Hnrnpk+/ mice (2 of 55; 4%) developed hepatocellular
carcinomas (Figure 6F). These findings indicate that hnRNP K
plays a significant role in preventing tumor formation and further
suggest that hnRNP Kmay function as a previously uncharacter-
ized tumor suppressor.
Reduced hnRNP K Expression Results in Altered
Cytokine Signaling and Increased Proliferation
and Differentiation Potential
To gain an understanding of the molecular pathways altered by
diminished hnRNP K expression, we evaluated cytokine levels
in wild-type (n = 10) and Hnrnpk+/ (n = 9) mouse sera. Interest-
ingly, Hnrnpk+/ mice had a significantly higher serum concen-
tration of interleukin-3 (IL-3) and IL-6, which are well known to
drive myeloproliferation and differentiation (Figure 7A). Addition-
ally, we found that serum levels of granulocyte-macrophage
colony-stimulating factor (GM-CSF) and granulocyte-colony
stimulating factor (G-CSF), which are required for propagation
of the myeloid lineage, were also significantly increased in
Hnrnpk+/ mice (Figure 7A). Since myeloproliferation can occur
as a result of an acute inflammatory process (Gabay and Kush-
ner, 1999), we evaluated global inflammation by examining
expression of C-reactive protein in the livers and bone marrows
of wild-type and Hnrnpk+/ mice. We observed no significant
difference in the levels of C-reactive protein in Hnrnpk+/ mice
and wild-type littermates (Figure S5), indicating an acute phase
response is not the primary source of these myeloproliferative
phenotypes.
Given the significant changes in cytokine levels observed in
Hnrnpk+/ mice, we next evaluated the impact that these spe-
cific cytokines have on myeloproliferative potential in Hnrnpk+/
HSCs using in vitro colony formation assays. Lin-CD117+ HSCs
from Hnrnpk+/mice exhibited a significant increase in prolifera-
tion and differentiation potential when compared with wild-type
Lin-CD117+ HSCs grown in MethoCult (Figure 7B). To further
explore the replicative potential of Hnrnpk+/ HSCs, we per-
formed replating in vitro colony formation assays. Hnrnpk+/
HSCs displayed higher replating potential than wild-type
HSCs, as Hnrnpk+/ HSCs had a significant increase in the
number of colonies at each replating and sustained their
AB
Figure 5. Hnrnpk+/– Mice Develop Myeloid Hyperplasia
(A) Cell blood count of peripheral blood (PB) comparing neutrophils (p = 0.0006) and basophils (p = 0.0477) from wild-type (n = 8) and Hnrnpk+/ (n = 11) mice
and platelets (p = 0.0095) of wild-type (n = 6) and Hnrnpk+/ (n = 6) mice.
(B) Flow cytometry analysis of double positive Ly6G/CD11b myeloid populations (50,000 gated cells) in the PB of wild-type (n = 6) and Hnrnpk+/ (n = 6)
(upper panel, p = 0.0354) and bone marrow of wild-type (n = 7) and Hnrnpk+/ (n = 13) (bottom panel, p = 0.0008) mice. BM, bone marrow.
Percentages were compared and analyzed using the Mann-Whitney test. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.005. See
also Figure S3.proliferation and differentiation potential for more passages
(Figure 7C). Together, these findings suggestHnrnpk haploinsuf-
ficiency and cytokine signaling may cooperate to disrupt
hematopoietic homeostasis leading to proliferative and differen-
tiation defects.
Hnrnpk+/– HSCs Develop Myeloid Proliferative and
Malignant Lymphoid Phenotypes in Transplanted Mice
To more fully understand the replicative potential of Hnrnpk+/
HSCs and determine whether transplantation of these cells
could give rise to malignancies, we isolated Lin-CD117+ HSCs
from three separate CD45.2+ Hnrnpk+/ and wild-type mice
and injected them into irradiated CD45.1+ NOD.Cg-Prkdc(scid)
Il2rg(tm1Wjl)/SzJ (NSG) recipient mice. While we observed engraft-
ment of CD45.2+ HSCs isolated from both Hnrnpk+/ and wild-Ctype mice in the recipient CD45.1+ NSG mice, two out of
the three NSG mice transplanted with Hnrnpk+/ HSCs had
a significant expansion of the myeloid compartment with a
hypereosinophilic phenotype compared with NSG mice trans-
planted with wild-type HSCs (Figures 7D and 7E). Interestingly,
the remaining NSG mouse transplanted with the Hnrnpk+/
HSCs did not develop a myeloproliferative phenotype but
instead developed a malignant lymphoma phenotype marked
by expansion of aberrant lymphocytes (Figure 7F). These mice
displayed medium to large lymphoma cells in the peripheral
blood with irregular nuclear contours, small nucleoli, and
basophilic cytoplasm. Together, these transplantation data
indicate the cell autonomous ability of Hnrnpk+/ HSCs to drive
these malignant phenotypes independent of the Hnrnpk+/
microenvironment.ancer Cell 28, 486–499, October 12, 2015 ª2015 Elsevier Inc. 491
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Figure 6. Hnrnpk+/– Mice Have Reduced
Survival and Are Tumor Prone
(A) Kaplan-Meier curves indicating survival of
Hnrnpk+/ (n = 76) and wild-type (n = 37) mice.
Statistical significance was determined by the log
rank test (p = 0.0001).
(B) Hnrnpk haploinsufficiency results in tumor
phenotypes (n = 55; 62% myeloproliferation, 31%
lymphoma, and 4% hepatocellular carcinoma).
(C) H&E staining of paraffin-embedded bone
marrow sections and peripheral blood (PB) smears
from wild-type Hnrnpk+/ mice diagnosed with
myeloid hyperplasias. The scale bar for H&E
staining represents 125 mm and 50 mm for PB
smears. BM, bone marrow.
(D) H&E staining of paraffin-embedded splenic
sections and PB smears from wild-type and lym-
phoma burdened Hnrnpk+/ mice.
(E) H&E and immunohistochemical staining of
malignant T cell (CD3 positive, bottom panel) and B
cell (B220 positive, top panel) lymphomas in the
liver of Hnrnpk+/ mice.
(F) H&E staining of paraffin-embedded liver sec-
tions from wild-type and Hnrnpk+/ mice diag-
nosed with hepatocellular carcinoma.
See also Figure S4.Diminished hnRNPKExpressionResults in Deregulation
of Proliferation and Differentiation Pathways
In order to examine the molecular mechanisms that contribute
to the observed hematopoietic alterations, we isolated tissues
from Hnrnpk+/ and wild-type mice and evaluated expression
of genes known to influence myeloproliferative neoplasms.
Hnrnpk+/ mice had significantly reduced expression of the
differentiation factors C/EBPa and b in the bonemarrow and liver
(Figures 8A and 8B). Interestingly, only one isoform of C/EBPa—
C/EBPa p42—appeared to be reduced in an hnRNP-K-depen-
dent manner (upper band, denoted by arrowhead, Figure 8A).
In addition, reduced hnRNP K levels were associated with
reduced expression of its transcriptional target p21 (Figure 8C)
and activation of STAT3 as determined by phosphorylation of
tyrosine 705 (Figure 8D). Given the role of hnRNP K in transcrip-
tional regulation and the fact that p21, C/EBPa, and C/EBPb
contain putative hnRNP K DNA binding sites (Lynch et al.,
2005), we next performed hnRNP-K-specific chromatin immu-
noprecipitation (ChIP) assays. These experiments revealed
that hnRNP K directly interacted with the p21, C/EBPa, and C/
EBPb genes (Figures 8E and S6A). Importantly, hnRNP K binding492 Cancer Cell 28, 486–499, October 12, 2015 ª2015 Elsevier Inc.to these targets was significantly dimin-
ished in Hnrnpk+/ tissues. Our observa-
tion that the p42 isoform of C/EBPa was
reduced in Hnrnpk+/ tissues, coupled
with hnRNP K’s putative translational
activity, suggested hnRNP K may also
interact with the C/EBPa transcript. To
examine this, we performed RNA immu-
noprecipitation assays and observed a
significant interaction between hnRNP K
and the C/EBPa transcript in both wild-
type murine tissues and in the humanleukemic cell line HL-60 (Figures 6B, S6B, and S6C). However,
in Hnrnpk+/ samples, the interaction between hnRNP K and
C/EBPa was reduced. Together, these data suggest that
hnRNP K may directly regulate cellular differentiation through
the C/EBP pathways and proliferation through the p53/p21 and
JAK/STAT pathways.
We next examined expression changes in genes known to be
deregulated specifically in lymphomas and thought to be regu-
lated by hnRNP K. Lymphomas from Hnrnpk+/ had significantly
elevated levels of tumor necrosis factor alpha (TNF-a), an acti-
vator of cell proliferation, and increased phos-Stat3 levels
compared with wild-type mice (Figures 8F and 8G, bottom
panels). Similar to the increased proliferation potential observed
in the myeloid compartment, we also observed malignant phe-
notypes arising in lymphoid lineages. Interestingly, in the sera
of these mice, we also observed an increase in the pro-lymphoid
cytokines IL-2, IL-10, and TNFa (Figure S6D). These findings
suggest the impact of reduced hnRNP K expression may occur
at an early hematopoietic precursor stage and that hnRNP-K-
mediated alterations in specific targets may dictate phenotypic
manifestations.
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Figure 7. hnRNP-K-Mediated Activation of Cytokines Contributes to Proliferation and Differentiation Phenotypes
(A) Cytokines array analysis of IL-3, IL-6, G-CSF, and GM-CSF levels in the peripheral blood of wild-type (n = 10) and Hnrnpk+/ mice (n = 9) diagnosed with
myeloid hyperplasia (IL-3: p = 0.0002; IL-6: p = 0.0004; G-CSF: p = 0.0002; GM-CSF: p = 0.0002).
(B) Analyses of colony formation assays after 14 days using Lin-CD117+ hematopoietic stem cells from wild-type (n = 8) and Hnrnpk+/ (n = 17) mice (number of
colonies: p = 0.0078; number of cells: p = 0.0001). All experiments were performed in triplicate. Data are represented as mean ± SEM. **p < 0.01 and ***p < 0.005.
p values were calculated using the Mann-Whitney test.
(C) Replating analysis of Lin-CD117+ hematopoietic stem cells from wild-type (n = 5) and Hnrnpk+/ (n = 7) mice. Each passage was analyzed every 14 days.
All experiments were performed in quadruplicate. Data are represented as mean ± SEM.
(D) Flow cytometry analysis of CD45.1+ (host) and CD45.2+ (donor) in the transplanted host mice and B220+ and Ly6G+ cells within the CD45.2+ population.
(E) Cell blood count analysis of untransplanted NSG (control) mice and NSG mice transplanted with wild-type or Hnrnpk+/ HSCs.
(F) Wright’s staining of peripheral blood (PB) smears from NSG mice transplanted with wild-type or Hnrnpk+/ HSCs harboring malignant lymphoid cells.
See also Figure S5.
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Figure 8. Hnrnpk Haploinsufficiency Alters
Expression of Genes Controlling Prolifera-
tion and Differentiation
(A) Western blot analysis of C/EBPa and C/EBPb
from lysates of wild-type and Hnrnpk+/ mice. The
upper arrow denotes the p42 isoform of C/EBPa
and the lower arrowmarks the p30 isoform. b-actin
serves as a loading control.
(B) qRT-PCR analysis of C/EBPa and C/EBPb
levels fromwhole bonemarrows of wild-type (n = 8)
and Hnrnpk+/ (n = 10) mice (C/EBPa: p = 0.042;
C/EBPb: p = 0.020).
(C) qRT-PCR analysis of p21 levels in wild-type
(n = 8) and Hnrnpk+/ (n = 10) bone marrows
(p = 0.0044).
(D) Immunohistochemical analysis of phos-
Y705Stat3 levels in the bone marrow wild-type
and Hnrnpk+/ mice diagnosed with myeloid hy-
perplasia. The scale bar represents 125 mm.
(E) ChIP analysis of hnRNP K interacting with the
C/EBPa, C/EBPb, and p21 genes in wild-type or
Hnrnpk+/ tissues. Each rectangle represents the
corresponding gene. The closed black box de-
noted the region harboring a putative hnRNP K
binding sequence that is amplified by the corre-
sponding primer sets. The ‘‘checkmark’’ denotes
positive hnRNP K binding and the ‘‘X’’ denotes a
lack of interaction.
(F) qRT-PCR analysis of TNFa levels in spleens
from wild-type (n = 7) and tumor burdened
Hnrnpk+/ (n = 5) mice (p = 0.0177).
(G) H&E staining and immunohistochemical ana-
lyses of B220, TNFa, and phos-Y705STAT3
expression in Hnrnpk+/ mice with malignant
lymphoid infiltration in the liver.
Data are represented as mean ± SEM. *p < 0.05
and ***p < 0.005. p values were calculated using
unpaired t and Mann-Whitney tests. See also
Figure S6.DISCUSSION
Over the past decade, in vitro and biochemical studies have
shown that hnRNP K impacts cellular programs that influence
cancer development (Notari et al., 2006). As such, clinical asso-
ciation studies have implicated that changes in hnRNP K expres-
sion are associated with disease phenotypes (Cancer Genome
Atlas Research Network, 2013; Enge et al., 2009; Kro¨nke et al.,
2013; Moumen et al., 2005; Roychoudhury and Chaudhuri,
2007). In this study, we examined how reduced hnRNPK expres-494 Cancer Cell 28, 486–499, October 12, 2015 ª2015 Elsevier Inc.sion influences malignant phenotypes in
the hematopoietic compartment. Herein,
we demonstrate that HNRNPK expres-
sion is significantly reduced in patients
with AML that carry a 9q21.32 deletion.
To fully examine the role of hnRNP K
in vivo, we generated an Hnrnpk+/
mouse model, which potentially mimics
the genetic loss observed in AML patients
with 9q21.32 deletions. Here, we report
that hnRNPK is critical for embryogenesis
and development, as biallelic deletion ofHnrnpk results in embryonic lethality prior to day 13.5 in utero,
while haploinsufficiency results in a partial neonatal lethal pheno-
type and developmental defects. Hnrnpk+/ mice displayed a
significant reduction in survival and a highly penetrant cancer
phenotype, as defined by lymphomas, myeloproliferation, and
hepatocellular carcinomas. Reduced hnRNP K expression
contributed to these phenotypes by disrupting differentiation
and proliferation pathways and through decreased genomic sta-
bility. These results indicate that hnRNP K is a tumor suppressor
that may influence proliferation and differentiation activities.
The role of hnRNP K in tumor formation has been difficult to
address because of the number of cellular processes it regu-
lates. On one hand, hnRNP K overexpression has been reported
in some solid tumors and associates with poor clinical status
(Matta et al., 2009; Roychoudhury and Chaudhuri, 2007). In
studies using chronic myeloid leukemia (CML) cell lines, the
oncogenic potential of the BCR-ABL fusion gene appears to
be dependent on hnRNP K, suggesting hnRNP K may play a
role in the BCR-ABL-mediated oncogenic addiction (Notari
et al., 2006). In fact, short hairpin RNA (shRNA) knockdown of
hnRNP K in these cells resulted in decreased differentiation
potential and uncovered the fact that hnRNPK’s translational
functions, but not its transcription functions, contribute to the
oncogenic potential of BCR-ABL. Furthermore, experiments in
pancreatic cancer cells revealed that small interfering RNA
(siRNA)-mediated knock down of hnRNP K resulted in an inhibi-
tion of proliferation (Zhou et al., 2010). When hnRNP K is overex-
pressed in cell lines, this cytoplasmic portion became elevated
where it was shown to influence the activity of c-Src (Ostar-
eck-Lederer et al., 2002). Taken as a whole, these observations
suggest that when hnRNP K is overexpressed, it may possess
oncogenic functions through its translational and cytoplasmic
functions.
In contrast, biochemical and clinical data suggest hnRNP K
loss may influence tumorigenesis as well. hnRNP K has been
shown to influence the tumor suppressive activities of p53
(Enge et al., 2009; Moumen et al., 2005), and in AML, hnRNP K
is deleted in a subset of AML patients (Kro¨nke et al., 2013).
Furthermore, mutations in hnRNP K have also been implicated
in driving AML progression (Cancer Genome Atlas Research
Network, 2013). These findings indicate that hnRNPK potentially
functions as a tumor suppressor through the p53 pathway and
that its loss may directly result in malignant phenotypes. This
notion of hnRNP K as having a role in tumor suppression gained
significant traction following biochemical and cell line studies
that revealed hnRNP K was required for activation of p21 in a
p53-dependent manner following DNA damage or treatment
with preclinical compounds that reactivate mutant p53 func-
tions. To examine how hnRNP K impacts p21 activation in a
genetically defined system, we treated Hnrnpk+/ MEFs with
ionizing radiation and observed a significant hnRNP-K-depen-
dent reduction in p21 activation. Using an in vivo approach,
we determined that p21 levels were significantly decreased
in tissues from Hnrnpk+/ mice. Furthermore, this in vivo regula-
tion appears to be a consequence of a physical interaction
between hnRNP K and the p21 gene. Together, these in vitro
and in vivo results indicate that hnRNP K is indeed a direct
regulator of p21 activation, and loss of this hnRNP-K-mediated
activity partially explains the observed proliferative phenotypes
observed in the MEFs and tissues of Hnrnpk+/ mice.
In addition to influencing proliferative programs, hnRNP K has
also been implicated in regulating cellular differentiation. In our
study, we observed that C/EBPa and b were significantly
deregulated in tissues from Hnrnpk+/ mice. While recent
ChIP-seq studies in cell lines suggest hnRNP K may directly
modulate C/EBPb expression by specifically interacting with its
promoter (Mikula et al., 2013), less is known regarding how
hnRNP K regulates C/EBPa levels. Examination of the potential
interaction between hnRNP K and the C/EBPa and C/EBPbCgenes revealed that hnRNP K directly interacts with both genes.
Similar to our observation at the p21 promoter, reduced hnRNP
K expression also resulted in decreased binding at these sites.
Interestingly, we observed that the C/EBPa p42 isoform, but
not p30, was significantly downregulated in Hnrnpk+/ mice,
suggesting that changes in hnRNP K expression altered expres-
sion of the C/EBPa p42 isoform only. The observed changes in
the expression ratio of C/EBPa isoforms (e.g., p42 to p30) may
have a significant impact on the myeloproliferative phenotypes
observed in the Hnrnpk+/ mice, as deregulation of the p42
isoform significantly alters myelogenesis (Schuster et al., 2013)
and the p30 isoform does not possess the anti-mitotic activity
of the p42 isoform (Nerlov, 2004). As such, the p42 isoform has
been identified as a myeloid tumor suppressor, as its absence
allows for alterations in lineage commitment and unchecked
myeloid proliferation (Kirstetter et al., 2008). Because of leaky
ribosomal scanning, both the p42 and p30 isoforms of C/EBPa
are translated from the same mRNA (Hsieh et al., 1998). Given
the known translational activity of hnRNP K, and our observation
that hnRNP K interacts with C/EBPa mRNA, it is plausible that
hnRNP Kmay also influence the expression of C/EBPa isoforms.
Taken together, these findings suggest perturbations in hnRNP
K levels deregulate C/EBP expression leading to a failure in
maintaining a homeostatic balance in hematopoietic differen-
tiation that culminates in the observed myeloproliferative
phenotypes.
In contrast to the C/EBPa p42 mouse model (Kirstetter et al.,
2008) that produces a myeloid hyperplasia phenotype with high
levels of CD11b+/Ly6G- cells, Hnrnpk+/ mice displayed high
levels of CD11b+/Ly6G+ cells, suggesting reduced hnRNP K
expression likely contributes to alterations in differentiation
potential through additional mechanisms outside of the C/
EBP pathway. As such, we observed a significant increase in
cytokines that regulate proliferation and differentiation potential
(e.g., IL-3, IL-6, GM-CSF, and G-CSF) and that are required for
transitioning HSCs to the myeloid lineage. Together, these
additional factors may be a necessary and sufficient secondary
input required for HSCs to develop into myeloid malignancies.
To examine the interplay between HSC maturation and myeloid
proliferation and differentiation defects, we used in vitro cyto-
kine dependent colony formation assays. These experiments
demonstrated that Hnrnpk haploinsufficiency led to increased
differentiation and proliferation potential in HSCs. Furthermore,
replating in vitro cytokine-dependent colony formation assays
demonstrated the ability of Hnrnpk+/ HSCs to be serially prop-
agated, indicating the increased long-term replicative potential
of the Hnrnpk+/ HSCs. Given that cytokines necessary for
HSCs to transition into myeloid and lymphoid lineages (e.g.,
IL-2, IL-10, and TNFa; Figure S6D) were significantly upregu-
lated in Hnrnpk+/ mice, these in vivo events may simply be a
consequence of aberrant cytokine production specific to the
Hnrnpk+/ bone marrow niche. To test the possibility, we trans-
planted Lin-CD117+ Hnrnpk+/ cells into recipient NSG mice.
Critically, Hnrnpk+/ HSCs had the capacity to trigger myelo-
proliferative and lymphoma phenotypes independent of the
Hnrnpk+/ microenvironment. Together, these results indicate
the Hnrnpk+/ HSCs, by themselves, have the capacity to
induce cancer processes and stimulate these proliferative
phenotypes.ancer Cell 28, 486–499, October 12, 2015 ª2015 Elsevier Inc. 495
In myeloproliferative neoplasms, as well as other cancers, the
JAK/STAT pathway is a critical hub that links cytokine signaling
with transcriptional programs controlling proliferation and differ-
entiation potential (Quinta´s-Cardama and Verstovsek, 2013).
Consistent with our findings of increased IL-3 and IL-6 in
Hnrnpk+/ mice, we observed a significant increase in STAT3
activation in the myeloproliferative bone marrows. In patients
with myeloproliferative neoplasms (MPNs), activation of the
JAK2/Stat pathway commonly results from activating mutations
in JAK2 (V617F) (James et al., 2005). However, our data suggest
that reduced hnRNP K expression also results in a similar activa-
tion of the STAT pathway but without the need for JAK2 muta-
tions. Thus, reduced hnRNP K expression may serve as an initial
event to stimulate proliferation and force cancer phenotypes.
The relationship between hnRNP K and STAT3 may not be
exclusively related to the granulocytic compartment, as JAK2
mutations leading to STAT3/5 activation are commonly
observed in patients with essential thrombocythemia (Quinta´s-
Cardama and Verstovsek, 2013). Likewise, we observed a
substantial number of Hnrnpk+/ bone marrows that displayed
megakaryopoietic phenotypes (Figure S4B). These data support
the idea that hnRNP K is a critical factor that regulates the
transition of committed myeloid progenitors to terminally
differentiated hematopoietic lineages through activation of cyto-
kine- and Stat3-dependent pathways. In addition to controlling
myeloid hyperplasia, activation of STAT3 also promotes B cell
proliferation and is associated with poor overall survival in pa-
tients with diffuse large B cell lymphoma (Huang et al., 2013).
Similar to these findings, we observed that hnRNP-K-mediated
STAT3 activation also contributed to lymphomogenesis in
Hnrnpk+/ mice. Together, these results indicate that hnRNP K
loss significantly influences STAT3 activation, which directly
contributes to the differentiation and proliferation defects in the
hematologic compartment of Hnrnpk+/ mice.
In this study, we present in vivo evidence that hnRNP K is
directly involved in cancer development. Clinical studies have re-
vealed that the HRNPK gene resides in the MDR of the 9q21.32
locus, which is lost in a subset of patients with AML (Dayyani
et al., 2008; Kro¨nke et al., 2013; Sweetser et al., 2005), suggest-
ing alterations in hnRNP K expression associate with leukemo-
genesis in these patients. Given that hnRNP K expression has
not been examined in primary AML patient samples that harbor
a 9q deletion, we evaluated whether the remaining HNRNPK
allele could compensate for the deleted gene in maintaining
wild-type hnRNP K expression levels. In our 9q deleted AML
patient samples, we observed a dramatic decrease in HNRNPK
levels, suggesting this loss contributed to the disease process
(Figure 1). This finding may have significant translational applica-
tions, as there are currently no targeted therapies for patients
with AML that harbor a 9q21.32 deletion. Thus, a better under-
standing of how hnRNP K influences the p53/p21 and STAT3
pathways could lead to management of this disease and the
development of tailored therapeutic regimens for these individ-
uals. Therapies that reactivate the p53 pathway (e.g., nutlin-3)
or disrupt the STAT3 pathway (ruxolitinib or AZD9150, a STAT3
inhibitor currently in clinical trial) could be therapeutically benefi-
cial and used to enhance current treatment strategies.
On the basis of data from our Hnrnpk+/ mouse model, we
demonstrate that hnRNP K behaves as a tumor suppressor496 Cancer Cell 28, 486–499, October 12, 2015 ª2015 Elsevier Inc.through its regulation of p21 and the p42 isoform of C/EBPa.
However, there are also clinical association data and cell line
studies suggesting that hnRNP K may also have a role in onco-
genesis. These two dichotomous results suggest that a homeo-
static balance in hnRNP K expression must be maintained for
proper cellular regulation and to prevent tumorigenesis. Thus,
any disequilibrium in expression (reduced or increased) could
result in dire consequences. Similar to the importance of our
Hnrnpk+/mouse model in determining that hnRNP K has tumor
suppressive functions, the generation of mouse models that
overexpress hnRNP K will be critical for determining whether
hnRNP K has oncogenic potential and if its overexpression
directly impacts tumor formation in vivo. These overexpression
models could be employed to examine a causal relationship
between increased hnRNP K levels and changes in its cellular
localization, its direct influences on c-Myc expression, and its
interaction with kinases such as c-Src.
In summary, our findings demonstrate thatHnrnpk haploinsuf-
ficiency results in highly penetrant and transplantable cancer
phenotypes, particularly in the hematological compartment
with expansion of myeloid lineages, and a significant reduction
in survival. Reduced hnRNPK levels contributed to these pheno-
types by deregulating proliferation and differentiation programs
through its control of the p53/p21 and C/EBP pathways, dereg-
ulation of cytokines, and STAT3 activation. Our clinical data
suggest changes in hnRNP K levels associate with myeloid
malignancies as hnRNP K expression is reduced in patients
with AML that carry 9q21.32 deletions. Together, these findings
suggest that hnRNP K is a tumor suppressor gene involved in
hematologic malignancies.
EXPERIMENTAL PROCEDURES
Analysis of HNRNPK Expression in AML Patient Samples
All 12 human AML patient samples were obtained from the AML tissue bank at
MD Anderson Cancer Center following protocol PA14-0478, which was
approved by the Institutional Review Board at MD Anderson. Patient consent
was obtained at the time of collection. All CD34+ cell examined harbored a
deletion of the 9q21.32 locus in greater than 50% of metaphases analyzed.
In addition to the 9q deletions, 3 out of 12 samples contained several additional
chromosomal aberrations, and 1 out of 12 harbored a t(8;21) translocation.
RNA from Ficoll-enriched mononuclear cells of AML patients (n = 12) and
wild-type donors (n = 8) was isolated and reverse transcribed to generate
cDNA. cDNAs were used in TaqMan assays to determine expression of
HNRNPK and two housekeeping control genes (GAPDH and b-ACTIN). All as-
says were performed in triplicate, and changes in expression were determined
by comparing HNRNPK expression with housekeeping controls (Pfaffl, 2001).
Generation of Hnrnpk+/– Mice
Mice carrying a knockout allele (Hnrnpktm1(KOMP)Wtsi) were generated using
KOMP-targeted JM8A1.N3 mESCs (a C57BL/6N strain). Quality control of
the mESCs was performed in the MD Anderson Genetically Engineered
Mouse Facility (GEMF). mESCs were injected into C57/Bl6 blastocysts using
standard procedures as previously performed in GEMF to generated chimeric
Hnrnpk+/ mice (Post et al., 2010). Because of a highly penetrant haploinsuffi-
cient lethal phenotype, only one viable Hnrnpk+/ mouse (a male) was gener-
ated on the C57Bl/6 mouse background. Sperm from this mouse was isolated
and used in in vitro fertilization (IVF) procedures to generate mice on a Balb/C
background. Balb/C;C57BL/6 hybrid mice were subsequently backcrossed
for three generations with wild-type Balb/C mice. These Hnrnpk+/ Balb/C
mice were used to generate the Hnrnpk+/ cohort. The neomycin cassette
was removed by crossing the Hnrnpk+/ mice with ZP-3 Cre expressing
mice. Females from these crosses were then bred to wild-type males. The
LacZ and neomycin cassette was removed by crossing Hnrnpk+/ mice with
mice expressing Flp recombinase. All mouse studies were conducted with
approval from the Institutional Animal Care and Use Committee (IACUC) at
MD Anderson Cancer Center under protocol 0000787-RN01.
Genotyping and Validation of the Hnrnpk Allele
PCR-based strategies using primer sets that were external and internal to both
50 and 30 arms were initially performed to confirm homologous recombination
and germline transmission. The 50 arm was verified by PCR amplification and
visualization using external primer 50-GCATAATAGCAACATATAAAGTTAC-30
(forward) and internal primers 50-AACCTTCCCCAACACCGAAACCAATG-30
(forward) and 50-CACAACGGGTTCTTCTGTTAGTCC-30 (reverse) primers.
The 30 arm was verified by external primers 50-CAGCATCAGCCACTTCCA
TAACC-30 (reverse) and 50-TGCCAATGTATTTTGTCTATGTCC-30 (reverse)
and internal primers 50-CAGTCTCAACTCGCAATCAAAGTCAC-30 (forward)
and 50-ATACTGTCGTCGTCCCCTCAAAC-30 (forward), as well as 50-GTTG
CAGTGCACGGCAGATACACTTGCTGA-30 (forward), 50-TTCGGCTATGACTG
GGCACAACAG-30(forward), and 50-CAACTGCCTAAGATGGAAGTAACCT-30
(reverse) primers. In addition to visualization of the PCR amplicon following
gel electrophoresis, PCR amplicons were purified and evaluated by Sanger
sequencing to confirm the sequence of the targeted allele. Additionally, the
lacZ reporter, neomycin cassette, Flp-FRT sites and loxP sites were evaluated
by PCR amplification and Sanger sequencing using primers 50-AACCTTCCC
CAACACCGAAACCAATG-30 (forward), GTGGCTTCAATTACCCTTTCTTGG
(forward), 50-AGTCCCAACCCCTTCCTCCTAC-30 (reverse), 50-CGACTCCTGAG
CCCGTCAGTATC-30 (forward), and 50-CCAAACTCATCAATGTATCTTATC-30
(reverse).
qRT-PCR
RNA from wild-type and Hnrnpk+/ mice bone marrows, HSCs, spleens, and
livers were extracted and purified using Tri Reagent (Sigma Aldrich). Purified
RNA was reverse transcribed using the iScript cDNA Synthesis kit (BioRad)
to generate cDNA. qRT-PCR was performed with iTaq UniveSYBR Green
SMX as per instructions on an ABI StepOnePlus Real-Time PCR System.
Details are described in Supplemental Experimental Procedures.
ChIP-qPCR
ChIP assays and quantification of chromatin interaction by real-time PCRwere
performed as described (Bochkis et al., 2008). p21, C/EBPa, and C/EBPb
primers selection was determined by in silico analyses of putative hnRNP K
binding motifs (TCCCCA) near the p21, C/EBPa, and C/EBPb loci (Lynch
et al., 2005). Details are described in Supplemental Experimental Procedures.
Western Blot
Western blot analyses were performed using protein lysates isolated from the
bone marrows, HSCs, spleens, and livers of wild-type and Hnrnpk+/ mice.
Primary antibodies used were hnRNP K (D-6, SantaCruz), C/EBPa (D56F10,
Cell Signaling), C/EBPb (LAP, Cell Signaling), and p21 (F-5, SantaCruz). Details
are described in Supplemental Experimental Procedures.
MEFs
MEFs from Hnrnpk+/ and wild-type mice were prepared from embryonic day
13.5 embryos and cultured in DMEM supplemented with 10% fetal calf serum
at 37C and 5% CO2. For analysis of proliferation, MEFs were equally plated,
collected at indicated time points, and counted using trypan blue exclusion
analysis or analyzed by WST-8 assay (Abnova) according to the manufac-
turer’s protocol. Prior to WST-8 analysis, cells were incubated with reconsti-
tuted WST-8 for 2 hr, and absorbance was read at a wavelength of 450 nm.
DNA Damage
For DNA damage experiments, MEFs were irradiated with 3 Gy ionizing radia-
tion and collected 3 hr post treatment.
Flow Cytometry
Flow cytometry was performed using cells from colony forming units, bone
marrows, and peripheral blood. Details are described in Supplemental Exper-
imental Procedures.CSurvival Analysis
Survival analysis was performed using the Kaplan-Meier method. Differences
between survival distributions were analyzed using the log rank test. Hazard
ratio and confidence interval was obtained by Mantel-Haenszel analysis.
Statistical computations were performed using GraphPad Prism 6.0.
Pathological Analysis and Immunohistochemistry
Moribund mice were sacrificed according to IACUC and MD Anderson guide-
lines under protocol 0000787-RN01. Details are described in Supplemental
Experimental Procedures.
Cytokine Multi-plex Assay
Sera from the peripheral blood of wild-type and Hnrnpk+/ mice were isolated
following high speed centrifugation. Cytokine levels were analyzed using the
Bio-Plex Pro Mouse Cytokine Multi-plex Assay (BioRad) according to the
manufacturing protocol. Results were processed on the Bio-Plex MAGPIX
Multiplex Reader (BioRad) and analyzed using the Bio-Plex manager software
with 5PL curve fitting.
Colony Formation Assay
HSCs (Lin-CD117+) were isolated from the bonemarrows ofHnrnpk+/ (n = 17)
and wild-type mice (n = 8) using CD117+ microbead kits (#130-091-224,
Miltenyi Biotech). 50,000 fractionated HSCs were cultured in triplicate wells
of a P24 plate in methylcellulose medium with cytokines (IL-3, 20 ng/ml;
IL-6, 20 ng/ml; erythropoietin [EPO], 3 units; stem cell factor [SCF], 50 ng/ml)
(MethoCult GF M3434, STEMCELL Technologies). Colony formation assays
using Hnrnpk+/ and wild-type Lin-CD117+ HSCs were performed in triplicate
for each sample. Results were read after 14 days by counting the number of
colonies and extracting the cells to perform viability assay (trypan blue) and
flow cytometry.
Colony Formation Replating Assay
Fourteen days after the initial colony formation assay,Hnrnpk+/ and wild-type
cells were harvested and resuspended in PBS. Viable cells were counted using
trypan blue, and 50,000 total cells were re-seeded in quadruplicate cultures in
methylcellulose medium supplemented with cytokines (IL-3, 20 ng/ml; IL-6,
20 ng/ml; EPO, 3 units; SCF, 50 ng/ml) (MethoCult GF M3434, STEMCELL
Technologies). This process was repeated on a 14-day cycle.
Transplant Assays
500,000 Lin-CD117+ cells from Hnrnpk+/ (n = 3) and wild-type (n = 3) were
injected into the tail veins of irradiated NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ
(NSG) mice. NSG mice were subjected to a non-lethal dose of g-irradiation
(2.5 Gy) 24 hr before injection of cells. Three months post injection,
mice were sacrificed and evaluated for alterations in the hematological
compartment between the Hnrnpk+/ and wild-type mice by cell blood
count and pathologic and flow cytometry analyses. Engraftment was
determined by flow cytometry using CD45.1-FITC and CD45.2-PE antibodies
(eBiosciences). Corresponding isotypes were used as controls. Subpopula-
tions of CD45.2+ cells were determined as above using FlowJo software
(http://www.flowjo.com/).
Statistical Analysis
Statistical analyses were performed using unpaired t andMann-Whitney tests.
p values less than 0.05 were considered statistically significant. The survival
curve used the Kaplan-Meier method. Differences between survival distribu-
tions were analyzed using the log rank test. Hazard ratios and confidence
intervals were obtained byMantel-Haenszel analysis. Statistical computations
were performed using GraphPad Prism 6.0.SUPPLEMENTAL INFORMATION
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